InMed Pharmaceuticals Inc. Common Shares (INM)

Price$1.58

Value ScoreB

Growth ScoreD

Momentum ScoreB

Favorite Metrics

Price vs S&P 500 (26W)10.87%

Price vs S&P 500 (4W)143.09%

VGM Score55.68

Market Capitalization$5.24M

All Metrics

Book Value / Share (Quarterly)$2.08

P/TBV (Annual)0.53x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)65.52%

Cash Flow / Share (Quarterly)$-2.25

Price vs S&P 500 (YTD)40.90%

Gross Margin (TTM)29.73%

Net Profit Margin (TTM)-170.19%

EPS (TTM)$-2.89

10-Day Avg Trading Volume0.23M

EPS Excl Extra (TTM)$-2.89

EPS (Annual)$-8.33

ROI (Annual)-62.77%

Gross Margin (Annual)34.53%

Net Profit Margin (5Y Avg)-601.10%

Cash / Share (Quarterly)$1.57

Revenue Growth QoQ (YoY)-26.22%

ROA (Last FY)-51.00%

Revenue Growth TTM (YoY)-6.73%

EBITD / Share (TTM)$-2.49

ROE (5Y Avg)-110.99%

Operating Margin (TTM)-173.52%

Cash Flow / Share (Annual)$-3.88

P/B Ratio0.76x

P/B Ratio (Quarterly)0.27x

EV / Revenue (TTM)0.02x

Net Interest Coverage (TTM)-32.42x

ROA (TTM)-69.37%

EPS Incl Extra (Annual)$-8.33

Current Ratio (Annual)7.07x

Quick Ratio (Quarterly)2.84x

3-Month Avg Trading Volume1.20M

52-Week Price Return-50.00%

Tangible BV / Share (Quarterly)$1.63

P/S Ratio (Annual)1.06x

Asset Turnover (Annual)0.31x

52-Week High$5.50

Operating Margin (5Y Avg)-625.01%

EPS Excl Extra (Annual)$-8.33

Tangible BV CAGR (5Y)20.62%

26-Week Price Return18.80%

Quick Ratio (Annual)6.37x

13-Week Price Return79.53%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)3.12x

Enterprise Value$77,300

Asset Turnover (TTM)0.37x

Book Value / Share Growth (5Y)-24.38%

Inventory Turnover (Annual)2.94x

Pretax Margin (Annual)-165.09%

Cash / Share (Annual)$5.56

3-Month Return Std Dev275.31%

Gross Margin (5Y Avg)33.37%

ROE (Last FY)-62.77%

Net Interest Coverage (Annual)-5.98x

EPS Basic Excl Extra (Annual)$-8.33

P/FCF (TTM)23.80x

Receivables Turnover (TTM)20.23x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.89

Receivables Turnover (Annual)12.09x

ROI (TTM)-82.16%

P/S Ratio (TTM)1.16x

Pretax Margin (5Y Avg)-600.97%

Revenue / Share (Annual)$5.04

Tangible BV / Share (Annual)$6.12

Price vs S&P 500 (52W)-74.37%

Year-to-Date Return49.06%

5-Day Price Return1.28%

EPS Normalized (Annual)$-8.33

ROA (5Y Avg)-84.40%

Net Profit Margin (Annual)-165.09%

Month-to-Date Return0.64%

Cash Flow / Share (TTM)$-2.20

EBITD / Share (Annual)$-7.90

Operating Margin (Annual)-160.85%

ROI (5Y Avg)-110.99%

EPS Basic Excl Extra (TTM)$-2.89

P/TBV (Quarterly)0.35x

P/B Ratio (Annual)0.47x

Inventory Turnover (TTM)3.09x

Pretax Margin (TTM)-169.09%

Book Value / Share (Annual)$6.92

Price vs S&P 500 (13W)71.27%

Beta0.96x

P/FCF (Annual)52.36x

Revenue / Share (TTM)$1.14

ROE (TTM)-82.16%

52-Week Low$0.57

vGradeB

gGradeD

mGradeB

vgmGradeC

Show chart for

Analyst Recommendations

Nov 2022

Dec 2022

Jan 2023

Feb 2023

2.25

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
INMInMed Pharmaceuticals Inc. Common Shares	B	D	B	$1.58
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

InMed Pharmaceuticals is a clinical-stage Canadian biopharmaceutical company developing small molecule therapies for rare diseases, with a pipeline including candidates for epidermolysis bullosa, glaucoma, and Alzheimer's disease. The company also operates BayMedica, a commercial segment producing rare cannabinoids for the health and wellness market.